Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of 24 weeks memantine add-on
treatment to risperidone for the treatment of negative symptomatology and cognitive
impairment in patients with chronic schizophrenia.